Halozyme and Baxter Expand Relationship

Halozyme Therapeutics, a development stage biopharmaceutical company focused on the development and commercialization of recombinant human enzymes, and Baxter Healthcare Corporation announced that they have expanded their relationship by signing a development and supply agreement for Enhanze SC, Halozyme's recombinant human hyaluronidase enzyme (rHuPH20).

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19545820&full=1)

(http://www.biospace.com/news_story.cfm?StoryID=19545820&full=1)